Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo(r)|Forsteo(r), to the EU, MENA, and ROW

MLA

“Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo(r)|Forsteo(r), to the EU, MENA, and ROW.” Plus Company Updates, 1 Mar. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.576991176&authtype=sso&custid=ns315887.

APA

Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo(r)|Forsteo(r), to the EU, MENA, and ROW. (2019, March 1). Plus Company Updates.

Chicago

Plus Company Updates. 2019. “Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo(r)|Forsteo(r), to the EU, MENA, and ROW,” March 1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.576991176&authtype=sso&custid=ns315887.